ArticleEuropean radiology2023
Prediction of Ki-67 labeling index, ATRX mutation, and MGMT promoter methylation status in IDH-mutant astrocytoma by morphological MRI, SWI, DWI, and DSC-PWI.
Article in European radiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Astrocytomas IDH-mutant of posterior cranial fossa, clinical presentation, imaging features and onco-functional balance in surgical management.Neurosurgical review · 2025Pooled it
- 7-T MRI intratumoral susceptibility signals reflect biomarker status in gliomas.European radiology experimental · 2026Article
- Virtual MR elastography and continuous-time random walk for predicting Ki-67 status in cervical cancer: a preliminary study.Frontiers in oncology · 2026Article
- Histogram analysis of IVIM MRI for differentiating glioma IDH-1 status, grade, and Ki-67 expression: a comparison of bi-exponential models at multiple B-value.BMC medical imaging · 2025Article
- NOD1/RIP2 Pathway Promotes Glioma Progression Through Microglial M2 Polarization.CNS neuroscience & therapeutics · 2025Article
- Velocity-Selective arterial spin labeling (VSASL) for cerebral blood volume assessment in gliomas: comparison with VSASL based cerebral blood flow and dynamic susceptibility contrast MRI.Neuroradiology · 2025Article
- Added prognostic value of histogram features from preoperative multi-modal diffusion MRI in predicting Ki-67 proliferation for adult-type diffuse gliomas.Quantitative imaging in medicine and surgery · 2025Article
- Continuous-time random walk and fractional order calculus models histogram analysis of glioma biomarkers, includingQuantitative imaging in medicine and surgery · 2025Article
- Diagnostic Utility of Intratumoral Susceptibility Signals in Adult Diffuse Gliomas: Tumor Grade Prediction and Correlation with Molecular Markers Within the WHO CNS5 (2021) Classification.Journal of clinical medicine · 2025Article
- Nomogram prediction of molecular characteristics in WHO grade 3-4 diffuse gliomas based on fractal analysis and VASARI features.Scientific reports · 2025Article
- The value of morphological magnetic resonance imaging features combined with diffusion kurtosis imaging for predicting Ki-67 expression levels in high-grade gliomas.Quantitative imaging in medicine and surgery · 2025Article
- Histogram analysis of diffusion weighted magnetic resonance imaging for predicting isocitrate dehydrogenase 1 mutation status in brain gliomas.Current journal of neurology · 2025Article
- MDPNet: a dual-path parallel fusion network for multi-modal MRI glioma genotyping.Frontiers in oncology · 2025Article
- Apparent diffusion coefficient predicts MGMT status in adult-type diffuse gliomas and is correlated with Ki-67 proliferation index.Frontiers in oncology · 2025Article
- Intra-tumoral susceptibility signals in brain gliomas: where do we stand?Frontiers in radiology · 2025Review
- Automated ITSS extraction combined with R2* values obtained from enhanced T2*-weighted angiography in magnetic resonance imaging: a promising approach for differentiate cervical adenocarcinoma from squamous carcinoma.Frontiers in oncology · 2025Article
- Multi-pool chemical exchange saturation transfer MRI in glioma grading, molecular subtyping and evaluating tumor proliferation.Journal of neuro-oncology · 2024Article
- Prediction of PD-L1 and Ki-67 status in primary central nervous system diffuse large B-cell lymphoma by diffusion and perfusion MRI: a preliminary study.BMC medical imaging · 2024Article
- Noninvasive assessment of Ki-67 labeling index in glioma patients based on multi-parameters derived from advanced MR imaging.Frontiers in oncology · 2024Article
- Assessment of Ki-67 expression levels in IDH-wildtype glioblastoma using logistic regression modelling of VASARI features.Neurosurgical review · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
objectiveNoninvasive detection of molecular status of astrocytoma is of great clinical significance for predicting therapeutic response and prognosis. We aimed to evaluate whether morphological MRI (mMRI), SWI, DWI, and DSC-PWI could predict Ki-67 labeling index (LI), ATRX mutation, and MGMT promoter methylation status in IDH mutant (IDH-mut) astrocytoma.
methodsWe retrospectively analyzed mMRI, SWI, DWI, and DSC-PWI in 136 patients with IDH-mut astrocytoma.The features of mMRI and intratumoral susceptibility signals (ITSS) were compared using Fisher exact test or chi-square tests. Wilcoxon rank sum test was used to compare the minimum ADC (ADC
resultsITSS, ADC
conclusionsmMRI, SWI, DWI, and DSC-PWI were shown to have the potential to predict Ki-67 LI and ATRX mutation status in IDH-mut astrocytoma. A combination of mMRI and SWI may improve diagnostic performance for predicting Ki-67 LI and ATRX mutation status. CLINICAL RELEVANCE STATEMENT: Conventional MRI and functional MRI (SWI, DWI, and DSC-PWI) can predict Ki-67 expression and ATRX mutation status of IDH mutant astrocytoma, which may help clinicians determine personalized treatment plans and predict patient outcomes. KEY POINTS: • A combination of multimodal MRI may improve the diagnostic performance to predict Ki-67 LI and ATRX mutation status. • Compared with IDH-mutant astrocytoma with low Ki-67 LI, IDH-mutant astrocytoma with high Ki-67 LI was more likely to show necrosis, edema, enhancement, poorly defined margin, higher ITSS levels, lower ADC, and higher rCBV. • ATRX wild-type IDH-mutant astrocytoma was more likely to show edema, higher ITSS levels, and lower ADC compared to ATRX mutant IDH-mutant astrocytoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.